Goldman Sachs
OPRX icon

Goldman Sachs’s OptimizeRx OPRX Stock Holding History

Goldman Sachs’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.25M Buy
358,443
+231,429
+182% +$2.15M ﹤0.01% 4436
2025
Q4 		$1.56M Sell
127,014
-9,450
-7% -$154K ﹤0.01% 4801
2025
Q3 		$2.8M Buy
136,464
+87,518
+179% +$1.39M ﹤0.01% 4182
2025
Q2 		$661K Sell
48,946
-2,061
-4% -$22.5K ﹤0.01% 4989
2025
Q1 		$442K Sell
51,007
-12,016
-19% -$73.4K ﹤0.01% 5260
2024
Q4 		$306K Buy
63,023
+29,798
+90% +$167K ﹤0.01% 5484
2024
Q3 		$256K Sell
33,225
-3,230
-9% -$28.7K ﹤0.01% 5370
2024
Q2 		$365K Buy
36,455
+21,985
+152% +$241K ﹤0.01% 5001
2024
Q1 		$176K Buy
14,470
+1,104
+8% +$16K ﹤0.01% 5147
2023
Q4 		$191K Sell
13,366
-30,985
-70% -$297K ﹤0.01% 5167
2023
Q3 		$345K Sell
44,351
-27,404
-38% -$298K ﹤0.01% 4831
2023
Q2 		$1.03M Sell
71,755
-13,334
-16% -$190K ﹤0.01% 4324
2023
Q1 		$1.24M Buy
85,089
+48,133
+130% +$805K ﹤0.01% 4224
2022
Q4 		$621K Sell
36,956
-22,188
-38% -$384K ﹤0.01% 4738
2022
Q3 		$876K Sell
59,144
-48,456
-45% -$958K ﹤0.01% 4604
2022
Q2 		$2.95M Buy
107,600
+28,966
+37% +$858K ﹤0.01% 3696
2022
Q1 		$2.96M Buy
78,634
+56,261
+251% +$2.49M ﹤0.01% 3874
2021
Q4 		$1.39M Sell
22,373
-48,527
-68% -$3.68M ﹤0.01% 4567
2021
Q3 		$6.07M Buy
70,900
+5,280
+8% +$331K ﹤0.01% 3191
2021
Q2 		$4.06M Sell
65,620
-23,527
-26% -$1.2M ﹤0.01% 3532
2021
Q1 		$4.35M Buy
89,147
+80,404
+920% +$3.88M ﹤0.01% 3256
2020
Q4 		$272K Sell
8,743
-48,608
-85% -$1.19M ﹤0.01% 4936
2020
Q3 		$1.2M Buy
+57,351
New +$985K ﹤0.01% 3952
2019
Q2 		– Sell
-27,193
Closed -$346K – 5294
2019
Q1 		$346K Buy
+27,193
New +$354K ﹤0.01% 4569

Other funds holding OPRX

WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's OPRX Position: Q1 2026 in Review

Goldman Sachs increased its OptimizeRx (OPRX) stake by 182% in Q1 2026, buying an estimated $2.15M and bringing the position to 358,443 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #4436.

Goldman Sachs first reported a position in OPRX in Q1 2019 and has held it in 24 quarters since. The position peaked at $6.07M in Q3 2021. 128 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

  • Goldman Sachs held 358,443 shares of OptimizeRx worth $2.25M as of Q1 2026.
  • Goldman Sachs bought 231,429 OptimizeRx shares in Q1 2026, an estimated $2.15M.
  • OptimizeRx made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4436 holding.
  • Goldman Sachs first reported a position in OptimizeRx in Q1 2019 and has held it in 24 quarters since.
  • Goldman Sachs's OptimizeRx position peaked at $6.07M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.